Clinical Trial Update: Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating MKC1106-MT in patients with melanoma reports safety data and immune responses from a multi-component immunotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MKC1106-MT

Snippet

Sponsor: Mannkind Corporation | Conditions: Advanced Melanoma, Stage III and IV Melanoma | Phase 1 | Status: COMPLETED